Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 11;14:1498579. doi: 10.3389/fonc.2024.1498579

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Lu, Ge, Liu, Zhu, Ye and Chang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

CXCR6 expression predicts the benefit of immunotherapy in bladder cancer. (A–C) Correlation between CXCR6 expression and immunotherapy benefit markers, including CD8A (A), effector T cell signature (B), and CD274 (PD-L1) (C), in bladder cancer, analyzed using GEPIA2. (D) Overview of the IMvigor210 clinical trial. (E, F) Comparison of immunotherapy outcomes in patients with high or low CXCR6 expression receiving anti-PD-L1 treatment. DCR, disease control rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. (G) CXCR6 expression levels across different anti-PD-L1 clinical response groups. (H) Kaplan-Meier survival analysis of patients with high or low CXCR6 expression receiving anti-PD-L1 immunotherapy. (I) CXCR6 expression levels among distinct tumor immune phenotypes.